US FDA approves GSK's Hepsavigo injection for chronic hepatitis B patients

mathrubhumi.com (Malayalam) — October 21, 2026 at 08:01 AM UTC

The US FDA has approved GSK's injection Hepsavigo (bepirovirsen) for chronic hepatitis B patients without cirrhosis, offering an alternative to antiviral drugs. The treatment targets genetic components that enable viral replication and protein production, allowing virus control without continuous medication. Patients receive injections for up to 24 weeks alongside existing antiviral therapy, followed by continued antiviral treatment for at least 24 more weeks. Possible side effects include liver reactions and decreased platelet counts, requiring regular blood tests. Chronic hepatitis B is a long-term liver infection; in 2019, hepatitis caused 1.1 million deaths worldwide, with 83 percent from hepatitis B.

With a significance score of 4.5, this news ranks in the top 4% of today's 32427 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:

Most significant articles on this story:

[5.0]

FDA Approves Bepirovirsen as First Antisense Therapy for Chronic Hepatitis B (contagionlive.com)

13h

Link Source

[4.5]

US FDA approves GSK's Hepsavigo injection for chronic hepatitis B patients (mathrubhumi.com)

22h

Link Source (Malayalam)

[4.4]

FDA Approves New Hepatitis B Treatment That May Replace Daily Antivirals (ndtv.com)

1d 1h

Link Source

[4.3]

GSK's Hibsago wins US approval for chronic hepatitis B treatment (ch.marketscreener.com)

1d 5h

Link Source (German)

[4.1]

US FDA approves GSK's hepatitis B drug, letting patients end long-term treatment (economictimes.indiatimes.com)

1d 1h

Link Source

[3.7]

FDA Approves Hepatitis B Drug That Helps Some Patients Stop Antivirals (timesnownews.com)

22h

Link Source